Metastatic Triple Negative Breast Cancer: The New Era of Thinking

[1] Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portrait of human breast tumors. Nature. 2000; 406:747–752. PerouCM SørlieT EisenMB van de RijnM JeffreySS ReesCA Molecular portrait of human breast tumors Nature 2000 406 747 752 10.1038/3502109310963602 Search in Google Scholar

[2] [Guideline] NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. V 1.2016. National Comprehensive Cancer Network. Available at http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Version 3.2018 – October 25, 2018; Accessed: December 7, 2018. [Guideline] NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. V 1.2016 National Comprehensive Cancer Network. Available at http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Version 3.2018 – October 25, 2018; Accessed: December 7, 2018. Search in Google Scholar

[3] Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J. Clin. Oncol. 2013: 31, 3997–4013. WolffAC HammondME HicksDG DowsettM McShaneLM AllisonKH Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update J. Clin. Oncol. 2013 31 3997 4013 10.1200/JCO.2013.50.998424101045 Search in Google Scholar

[4] Portha H, Jankowski C, Cortet M, Desmoulins I, Martin E, Lorgis V, Arnould L, Coutant C. [Nonmetastatic triple-negative breast cancer in 2016: Definitions and management]. Gynecol Obstet Fertil. 2016 Sep;44(9):492–504. PorthaH JankowskiC CortetM DesmoulinsI MartinE LorgisV ArnouldL CoutantC [Nonmetastatic triple-negative breast cancer in 2016: Definitions and management] Gynecol Obstet Fertil 2016 Sep 44 9 492 504 10.1016/j.gyobfe.2016.06.01427451066 Search in Google Scholar

[5] Prat A, Adamo B, Cheang MC. Molecular characterization of basal-like and non-basal-like triple-negative breast cancer. Oncologist. 2013; 18:123–33. PratA AdamoB CheangMC Molecular characterization of basal-like and non-basal-like triple-negative breast cancer Oncologist 2013 18 123 33 10.1634/theoncologist.2012-0397357959523404817 Search in Google Scholar

[6] Chandra D, Suresh P, Sinha R, Azam S, Batra U, Talwar V, Kumar K, Mehta A. Eight Year Survival Analysis of Patients with Triple Negative Breast Cancer in India. Asian Pac J Cancer Prev. 2016; 17:2995–9. ChandraD SureshP SinhaR AzamS BatraU TalwarV KumarK MehtaA Eight Year Survival Analysis of Patients with Triple Negative Breast Cancer in India Asian Pac J Cancer Prev 2016 17 2995 9 Search in Google Scholar

[7] Jia Jin, Yu Gao, Jian Zhang, Leiping Wang, Biyun Wang, Jun Cao, Zhimin Shao, Zhonghua Wang. Incidence, pattern and prognosis of brain metastases in patients with metastatic triple negative breast cancer. BMC Cancer. 2018; 18: 446. JinJia GaoYu ZhangJian WangLeiping WangBiyun CaoJun ShaoZhimin WangZhonghua Incidence, pattern and prognosis of brain metastases in patients with metastatic triple negative breast cancer BMC Cancer. 2018 18 446 10.1186/s12885-018-4371-0590925429673325 Search in Google Scholar

[8] Weigelt B, Ng CK, Shen R, Popova T, Schizas M, Natrajan R, et al. Metastatic breast carcinomas display genomic and transcriptomic heterogeneity. Mod Pathol. 2015; 28:340–351. WeigeltB NgCK ShenR PopovaT SchizasM NatrajanR Metastatic breast carcinomas display genomic and transcriptomic heterogeneity Mod Pathol 2015 28 340 351 10.1038/modpathol.2014.142452323925412848 Search in Google Scholar

[9] Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triplenegative breast cancer subtypes and preclinicalmodels for selection of targeted therapies. J Clin Invest. 2011; 121:2750–67. LehmannBD BauerJA ChenX SandersME ChakravarthyAB ShyrY Identification of human triplenegative breast cancer subtypes and preclinicalmodels for selection of targeted therapies J Clin Invest 2011 121 2750 67 10.1172/JCI45014312743521633166 Search in Google Scholar

[10] Lehmann BD, Pietenpol JA. Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes. J Pathol. 2014; 232:142–150. LehmannBD PietenpolJA Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes J Pathol 2014 232 142 150 10.1002/path.4280409003124114677 Search in Google Scholar

[11] Burstein MD, Tsimelzon A, Poage GM, Covington KR, Contreras A, Fuqua SA, et al. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res. 2015; 21:1688–1698. BursteinMD TsimelzonA PoageGM CovingtonKR ContrerasA FuquaSA Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer Clin Cancer Res 2015 21 1688 1698 10.1158/1078-0432.CCR-14-0432436288225208879 Search in Google Scholar

[12] Jézéquel P, Loussouarn D, Guérin-Charbonnel C, Campion L, Vanier A, Gouraud W, et al. Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response. Breast Cancer Res. 2015; 17:43. JézéquelP LoussouarnD Guérin-CharbonnelC CampionL VanierA GouraudW Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response Breast Cancer Res. 2015 17 43 10.1186/s13058-015-0550-y438940825887482 Search in Google Scholar

[13] Valentin MD, da Silva SD, Privat M, Molecular insights on basal-like breast cancer. Breast Cancer Res Treat. 2012; 134(1):21–30. ValentinMD da SilvaSD PrivatM Molecular insights on basal-like breast cancer Breast Cancer Res Treat 2012 134 1 21 30 10.1007/s10549-011-1934-z Search in Google Scholar

[14] Isakoff SJ, Mayer EL, He L, Traina TA, Carey LA, Krag KJ, et al. TBCRC009: A multicenter phase II clinical trial of platinum monotherapy with biomarker assessment in metastatic triple-negative breast cancer. J Clin Oncol 2015; 33: 1902–1909. IsakoffSJ MayerEL HeL TrainaTA CareyLA KragKJ TBCRC009: A multicenter phase II clinical trial of platinum monotherapy with biomarker assessment in metastatic triple-negative breast cancer J Clin Oncol 2015 33 1902 1909 10.1200/JCO.2014.57.6660 Search in Google Scholar

[15] Jiang Z, Jones R, Liu JC, Deng T, Robinson T, Chung PE, et al. RB1 and p53 at the crossroad of EMT and triple-negative breast cancer. Cell Cycle. 2011 ; 15;10:1563–70. JiangZ JonesR LiuJC DengT RobinsonT ChungPE RB1 and p53 at the crossroad of EMT and triple-negative breast cancer Cell Cycle 2011 15 10 1563 70 10.4161/cc.10.10.15703 Search in Google Scholar

[16] Pfister K, Pipka JL, Chiang C, Liu Y, Clark RA, Keller R, et al. Todd Stukenberg. Identification of Drivers of Aneuploidy in Breast Tumors Cell Rep. 2018 ; 29; 23: 2758–2769. PfisterK PipkaJL ChiangC LiuY ClarkRA KellerR Todd Stukenberg Identification of Drivers of Aneuploidy in Breast Tumors Cell Rep 2018 29 23 2758 2769 10.1016/j.celrep.2018.04.102 Search in Google Scholar

[17] Watkins JA, Irshad S, Grigoriadis A. Genomic scars as bio markers bio markers of homologous recombination deficiency and drug response in breast and ovarian cancers. Breast Cancer Res 2014; 16:211. WatkinsJA IrshadS GrigoriadisA Genomic scars as bio markers bio markers of homologous recombination deficiency and drug response in breast and ovarian cancers Breast Cancer Res 2014 16 211 10.1186/bcr3670 Search in Google Scholar

[18] Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med. 2017;377:523–533 RobsonM ImSA SenkusE XuB DomchekSM MasudaN Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation N Engl J Med 2017 377 523 533 10.1056/NEJMoa1706450 Search in Google Scholar

[19] Turner NC, Telli ML, Rugo HS, Mailliez M, J Ettl J, Grischke E-M, et al. Phase II ABRAZO: Talazoparib in gBRCA1/2 Mutation–Positive MBC.(Abstract 1007). Presented Jul 10 2017 ASCO Annual Meeting. TurnerNC TelliML RugoHS MailliezM J EttlJ GrischkeE-M Phase II ABRAZO: Talazoparib in gBRCA1/2 Mutation–Positive MBC.(Abstract 1007) Presented Jul 10 2017 ASCO Annual Meeting 10.1200/JCO.2017.35.15_suppl.1007 Search in Google Scholar

[20] Von Minckwitz G, Schneeweiss A, Loibl S, Salat C, Denkert C, Rezai M, Blohmer JU, et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a ran domised phase 2 trial. Lancet Oncol 2014; 15:747–56. Von MinckwitzG SchneeweissA LoiblS SalatC DenkertC RezaiM BlohmerJU Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a ran domised phase 2 trial Lancet Oncol 2014 15 747 56 10.1016/S1470-2045(14)70160-3 Search in Google Scholar

[21] Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxoru bicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol 2015; 33:13–21. SikovWM BerryDA PerouCM SinghB CirrincioneCT TolaneySM Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxoru bicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance) J Clin Oncol 2015 33 13 21 10.1200/JCO.2014.57.0572 Search in Google Scholar

[22] Hu XC, Zhang J, Xu BH, Cai L, Ragaz J, Wang ZH, et al. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol 2015; 16:436–46. HuXC ZhangJ XuBH CaiL RagazJ WangZH Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial Lancet Oncol 2015 16 436 46 10.1016/S1470-2045(15)70064-1 Search in Google Scholar

[23] Yardley DA, Brufsky A, Coleman RE, Conte PF, Cortes J, Glück S, et al. Erratum to: ‘Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial. Trials. 2016 Feb 3; 17:63. YardleyDA BrufskyA ColemanRE ContePF CortesJ GlückS Erratum to: ‘Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial Trials 2016 Feb 3 17 63 10.1186/s13063-016-1195-6473938926841937 Search in Google Scholar

[24] Tutt A, Ellis P, Kilburn L, Cheang M, Bliss J, Dowsett M, Flanagan J. et al. The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer. (Abstract S3-01). Presented at December 11, 2014. SABCS 2014. TuttA EllisP KilburnL CheangM BlissJ DowsettM FlanaganJ The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer. (Abstract S3-01) Presented at December 11, 2014 SABCS 2014 Search in Google Scholar

[25] Choi JE, Kang SH, Lee SJ and Bae YK. Androgen receptor expression predicts decreased survival in early stage triple-negative breast cancer. Ann Surg Oncol 2015; 22: 82–89. ChoiJE KangSH LeeSJ BaeYK Androgen receptor expression predicts decreased survival in early stage triple-negative breast cancer Ann Surg Oncol 2015 22 82 89 10.1245/s10434-014-3984-z25145503 Search in Google Scholar

[26] McGhan LJ, McCullough AE, Protheroe CA, Dueck AC, Lee JJ, Nunez-Nateras R, et al. Androgen receptor-positive triple negative breast cancer: a unique breast cancer sub type. Ann Surg Oncol 2014; 21: 361–367. McGhanLJ McCulloughAE ProtheroeCA DueckAC LeeJJ Nunez-NaterasR Androgen receptor-positive triple negative breast cancer: a unique breast cancer sub type Ann Surg Oncol 2014 21 361 367 10.1245/s10434-013-3260-724046116 Search in Google Scholar

[27] Gucalp A, Tolaney S, Isakoff SJ, Ingle JN, Liu MC, Carey LA, et al. Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast cancer. Clin Cancer Res 2013; 19:5505–12. GucalpA TolaneyS IsakoffSJ IngleJN LiuMC CareyLA Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast cancer Clin Cancer Res 2013 19 5505 12 10.1158/1078-0432.CCR-12-3327408664323965901 Search in Google Scholar

[28] Traina TA, Miller K, Yardley DA, O’Shaughnessy J, Cortes J, Gradishar W, et al. Results from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC). J Clin Oncol 2015; 33: S1003. TrainaTA MillerK YardleyDA O’ShaughnessyJ CortesJ GradisharW Results from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC) J Clin Oncol 2015 33 S1003 10.1200/jco.2015.33.15_suppl.1003 Search in Google Scholar

[29] Adams S, Schmid P, Rugo HS, Loi S, Toppmeyer D, Awada A, et al. Phase 2 study of pembrolizumab as first-line therapy for PD-L1–positive metastatic triple-negative breast cancer (mTNBC): Preliminary data from KEYNOTE-086 cohort B (Abstract 1008.) Presented June 3, 2017 ASCO Annual Meeting. AdamsS SchmidP RugoHS LoiS ToppmeyerD AwadaA Phase 2 study of pembrolizumab as first-line therapy for PD-L1–positive metastatic triple-negative breast cancer (mTNBC): Preliminary data from KEYNOTE-086 cohort B (Abstract 1008.) Presented June 3, 2017 ASCO Annual Meeting 10.1200/JCO.2017.35.15_suppl.1088 Search in Google Scholar

[30] Dalgleish AG. Rationale for combining immunotherapy with chemotherapy. Immunotherapy 2015;7:309–16. DalgleishAG Rationale for combining immunotherapy with chemotherapy Immunotherapy 2015 7 309 16 10.2217/imt.14.11125804482 Search in Google Scholar

[31] Kok M, Horlings HM, Vijver K. Russell N, Adaptive phase II randomized non-comparative trial of nivolumab after induction treatment in triple negative breast cancer: TONIC-trial (Abstract LBA14) Presented Mar 31, 2017 ESMO Annual Meeting. KokM HorlingsHM VijverK RussellN Adaptive phase II randomized non-comparative trial of nivolumab after induction treatment in triple negative breast cancer: TONIC-trial (Abstract LBA14) Presented Mar 31, 2017 ESMO Annual Meeting 10.1093/annonc/mdx440.006 Search in Google Scholar

[32] Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, et al; Atezolizumab and NabPaclitaxel in Advanced Triple Negative Breast Cancer. N Engl J Med. 2018;379:2108–2121. SchmidP AdamsS RugoHS SchneeweissA BarriosCH Atezolizumab and NabPaclitaxel in Advanced Triple Negative Breast Cancer N Engl J Med. 2018 379 2108 2121 10.1056/NEJMoa180961530345906 Search in Google Scholar

[33] Yam C, Mani SA, Moulder SL. Targeting the Molecular Subtypes of Triple Negative Breast Cancer: Understanding the Diversity to Progress the Field. Oncologist. 2017; 22:1086–1093. YamC ManiSA MoulderSL Targeting the Molecular Subtypes of Triple Negative Breast Cancer: Understanding the Diversity to Progress the Field Oncologist 2017 22 1086 1093 10.1634/theoncologist.2017-0095559919228559413 Search in Google Scholar

[34] Carey LA, Rugo HS, Marcom PK, Mayer EL, Esteva FJ, Ma CX, et al. TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol 2012; 30:2615–23. CareyLA RugoHS MarcomPK MayerEL EstevaFJ MaCX TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer J Clin Oncol 2012 30 2615 23 10.1200/JCO.2010.34.5579341327522665533 Search in Google Scholar

[35] Baselga J, Gómez P, Greil R, Braga S, Climent MA, Wardley AM, et al. Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer. J Clin Oncol 2013; 31:2586–92. BaselgaJ GómezP GreilR BragaS ClimentMA WardleyAM Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer J Clin Oncol 2013 31 2586 92 10.1200/JCO.2012.46.2408570519123733761 Search in Google Scholar

[36] Cortes J, O’Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, et al; EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician's. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011; 12; 377:914–23. CortesJ O’ShaughnessyJ LoeschD BlumJL VahdatLT PetrakovaK EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician's. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study Lancet 2011 12 377 914 23 10.1016/S0140-6736(11)60070-6 Search in Google Scholar

[37] Berkey CS, Rosner B, Tamimi RM, Willett WC, Hickey M, Toriola A, et al. Body size from birth through adolescence in relation to risk of benign breast disease in young women. Breast Cancer Res Treat. 2017;162:139–149. BerkeyCS RosnerB TamimiRM WillettWC HickeyM ToriolaA Body size from birth through adolescence in relation to risk of benign breast disease in young women Breast Cancer Res Treat 2017 162 139 149 10.1007/s10549-016-4084-5529008928062981 Search in Google Scholar

[38] Lehmann BD, Jovanović B, Chen X, Estrada MV, Johnson KN, Shyr Y, et al, Refinement of Triple Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection. PLoS One. 2016; 11: e0157368. LehmannBD JovanovićB ChenX EstradaMV JohnsonKN ShyrY Refinement of Triple Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection PLoS One 2016 11 e0157368 10.1371/journal.pone.0157368491105127310713 Search in Google Scholar

[39] Zhu Y, Zhao F, Li Z, Yu J. Current landscape and future directions of biomarkers for predicting responses to immune checkpoint inhibitors. Cancer Manag Res. 2018; 7; 10:2475–2488. ZhuY ZhaoF LiZ YuJ Current landscape and future directions of biomarkers for predicting responses to immune checkpoint inhibitors Cancer Manag Res 2018 7 10 2475 2488 10.2147/CMAR.S167400608611030122997 Search in Google Scholar

[40] Diéras V, Campone M, Yardley DA, Romieu G, Valero V, Isakoff SJ, et al. Randomized, phase II, placebo-controlled trial of onartuzumab and/or bevacizumab in combination with weekly paclitaxel in patients with metastatic triple-negative breast cancer. Ann Oncol 2015; 26: 1904–1910. DiérasV CamponeM YardleyDA RomieuG ValeroV IsakoffSJ Randomized, phase II, placebo-controlled trial of onartuzumab and/or bevacizumab in combination with weekly paclitaxel in patients with metastatic triple-negative breast cancer Ann Oncol 2015 26 1904 1910 10.1093/annonc/mdv26326202594 Search in Google Scholar

[41] Hon JD, Singh B, Sahin A, Du G, Wang J, Wang VY, et al. Breast cancer molecular subtypes: from TNBC to QNBC Am J Cancer Res 2016;6:1864–1872. HonJD SinghB SahinA DuG WangJ WangVY Breast cancer molecular subtypes: from TNBC to QNBC Am J Cancer Res 2016 6 1864 1872 Search in Google Scholar

[42] Barton VN, D’Amato NC, Gordon MA. Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR+ or Quadruple Negative Disease. Horm Cancer 2015; 6: 206–213. BartonVN D’AmatoNC GordonMA Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR+ or Quadruple Negative Disease Horm Cancer 2015 6 206 213 10.1007/s12672-015-0232-3689749926201402 Search in Google Scholar

[43] Paik S, Kim C, Wolmark N. HER2 status and benefit from adjuvant trastuzumab in breast cancer. N Engl JMed 2008; 358:1409–1411. PaikS KimC WolmarkN HER2 status and benefit from adjuvant trastuzumab in breast cancer N Engl JMed 2008 358 1409 1411 10.1056/NEJMc080144018367751 Search in Google Scholar

[44] Mittendorf EA, Ardavanis A, Symanowski J, Murray JL, Shumway NM, Litton JK, et al. Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence. Ann Oncol 2016; 27:1241–1248. MittendorfEA ArdavanisA SymanowskiJ MurrayJL ShumwayNM LittonJK Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence Ann Oncol 2016 27 1241 1248 10.1093/annonc/mdw150492231627029708 Search in Google Scholar

[45] Prat A, Perou CM. Mammary development meets cancer genomics. Nat Med. 2009; 15:842–4. PratA PerouCM Mammary development meets cancer genomics Nat Med 2009 15 842 4 10.1038/nm0809-84219661985 Search in Google Scholar